EVO

Based on Evotec SE's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Evotec SE do?

Evotec SE is a drug discovery and development partner for pharmaceutical and biotechnology companies. It provides integrated research services across biology, chemistry, and translational science, earning revenue through collaboration agreements, research fees, and milestone payments rather than selling finished medicines directly.

Does EVO pay dividends?

Evotec does not currently pay a dividend. The company retains capital to fund its research operations and partnership activities. Investors seeking regular income from their holdings would need to look at other stocks, as EVO does not distribute cash to shareholders at this time.

When does EVO report earnings?

Evotec reports financial results on a regular schedule consistent with its public listing obligations. Because milestone and collaboration timing can influence results significantly, watching for partnership announcements alongside earnings releases is worthwhile. Check Evotec's investor relations page for the current reporting calendar.

Is EVO a good stock to buy?

UQS Score rates EVO as Poor overall. The Quality and Moat pillars are both Weak, and Valuation is Elevated — a combination that warrants careful consideration. Risk is the relative strength. Investors should review the full pillar breakdown available to UQS Pro members before making any decision.

Is EVO overvalued?

The UQS Valuation pillar for EVO is rated Elevated, suggesting the current market price does not appear to offer a meaningful margin of safety relative to the company's underlying fundamentals. This is particularly notable given the Weak Quality and Moat ratings that accompany it.

How does EVO compare to its competitors?

Evotec's listed peers — Alvotech, Tilray Brands, and Collegium Pharmaceutical — each operate with distinct business models. Evotec's upstream discovery-and-partnership model differs from commercial-stage pharma or biosimilar manufacturing. UQS Pro members can view side-by-side pillar comparisons across these names.

What is EVO's market cap bracket?

Evotec SE is classified as a small-cap stock. This places it in a segment of the market that can carry higher volatility and liquidity considerations compared to large- or mega-cap peers, which is relevant context when assessing position sizing and risk.

Who founded Evotec SE?

Evotec was incorporated in 1993. The company was originally founded in Hamburg, Germany, and has grown through partnerships and acquisitions over the decades. Detailed founding history is publicly available through the company's official corporate communications and investor relations materials.

Is EVO a long-term quality investment?

As a long-term quality indicator, UQS Score rates EVO as Poor. The Weak Quality and Moat scores suggest the business has not yet demonstrated the durable earnings power and competitive defensibility typically associated with high-quality long-term holdings. The full analysis is available to Pro members.

What is the main competitive advantage of Evotec?

Evotec's value proposition lies in its integrated drug discovery platform and its established network of collaboration agreements with major pharmaceutical companies. However, the UQS Moat pillar is rated Weak, indicating that this advantage does not yet appear strongly defended against competitive pressure in the current assessment.

What sector does EVO belong to?

Evotec SE operates in the Healthcare sector, specifically within drug discovery and development services. It sits at the upstream end of the pharmaceutical value chain, providing research capabilities to companies that ultimately bring medicines to market.

Is EVO a growth stock or value stock?

Based on the UQS pillar profile, EVO carries a Neutral Growth rating and an Elevated Valuation rating — a combination that makes it difficult to classify cleanly as either. It does not currently exhibit the discounted pricing of a value stock, nor the strong growth momentum typically associated with high-conviction growth names.

Evotec SE currently shows below-average quality metrics, suggesting challenges with profitability.

Evotec SE faces growth headwinds with declining or stagnant revenue trends.

Evotec SE maintains a reasonable risk profile with manageable debt levels.

Evotec SE appears expensively valued relative to its fundamentals and growth prospects.

Evotec SE operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for EVO.

The UQS (Unified Quality Score) for Evotec SE is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Evotec SE's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Evotec SE is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.